I've always enjoyed your logic @alhambra.
Using your analogy of the 4 balls.
I remember SI mentioned that the P3 trials have 50% of success/ approval.
So we have 4 P3+ atm.
How would you rate them?
1. aGVHD - 99%; the ODAC 9-1 vote is very telling and therefore very difficult for the FDA to go against it. On what basis can they go against it? Maybe conditional approval, but FDA approval
2. Covid-19 ARDS; Given that aGVHD will be approved, EAP for MIS-C, and NIH sponsored trial. I would say this is likely. The only two concerns are when will the trial stop early due to overwhelming efficacy and producing large quantities. I'll say 75%
3. CLBP - let's leave this at 50% atm, until the readout
4. CHF - let's leave this at 50% atm, until the readout
So what has been priced in; and what hasn't?
With your clear and unbiased mind atm - can you provide a % of success the above?
- Forums
- ASX - By Stock
- Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19
I've always enjoyed your logic @alhambra.Using your analogy of...
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.8¢ |
Change
-0.068(6.34%) |
Mkt cap ! $1.141B |
Open | High | Low | Value | Volume |
$1.04 | $1.04 | 99.5¢ | $3.591M | 3.553M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
29 | 175179 | 99.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.00 | 18923 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 36652 | 1.000 |
22 | 176948 | 0.995 |
18 | 89667 | 0.990 |
7 | 107928 | 0.985 |
11 | 56262 | 0.980 |
Price($) | Vol. | No. |
---|---|---|
1.005 | 37014 | 13 |
1.010 | 84918 | 12 |
1.015 | 88446 | 9 |
1.020 | 76026 | 7 |
1.025 | 40418 | 5 |
Last trade - 15.57pm 04/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |